Open the mobile menu
Pancreatic cancer clinical study

Pancreatic cancer study

People with a specific type of BRCA-mutated metastatic pancreatic cancer (“germline” BRCA mutation, meaning associated with an inherited BRCA gene change) who have received initial chemotherapy and whose disease has now stabilized or improved may be eligible to take part in POLO, a clinical study supported by AstraZeneca, to help scientists find better treatment options for people living with pancreatic cancer.  This page provides further information about the POLO clinical trial.